PubMed Central® ID
Insulin therapy is frequently required to achieve glycemic targets (A1c) in type 2 diabetes (T2D); however, clinicians and patients face barriers with the complexities of multiple daily injection regimens. Patch-like wearable insulin devices, such as V-Go, may simplify and optimize this complexity. This study evaluated the change in A1C and insulin total daily dose (TDD) in a suboptimally-controlled (not achieving A1C targets) T2D population after switching to V-Go. A retrospective chart analysis at a diabetes clinic was performed to evaluate change in A1c measurements from baseline (V-Go initiation) to end of study observation. Of the 139 patients enrolled, A1C significantly decreased from baseline (-1.5 ± 1.79%;
V-Go, glycemic control, hemoglobin A1c, insulin, type 2 diabetes
Zeidan, Trisha; Nikkel, Carla; Dziengelewski, Beth; Wu, Stephanie; and Chen, Aleda, "Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis" (2020). Pharmacy Practice Faculty Publications. 412.